Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26
Details for Australian Patent Application No. 2007209787 (hide)
International Classifications
Event Publications
30 August 2007 Complete Application Filed
6 September 2007 Application Open to Public Inspection
Published as AU-B-2007209787
6 September 2007 Complete Application Filed
13 November 2008 Application Accepted
Published as AU-B-2007209787
12 March 2009 Standard Patent Sealed
28 April 2011 Application for Amendment
The nature of the amendment is: Amend patentee names to read Dana Farber Cancer Institute, Inc. and Board of Regents, The University of Texas System. Address for service in Australia - Pizzeys Level 2, Woden Plaza Offices Woden Town Square Woden Canberra ACT 2606
18 August 2011 Alteration of Name
The name of the patentee has been altered to Board of Regents, The University of Texas System; Dana Farber Cancer Institute, Inc.
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser